The Clinicians Speak, page-1017

Hi Festa
The recell process uses enzymatic dissolution of the skin cells to make a solution that can be spread across the wound using a small skin sample. This "seeds" the wound bed ideally with a similar cell mix to the lost skin to get a better cosmetic outcome.
The original method of harvest and sample preparation is very time consuming and variable. They would take the donor skin piece/s and chop it into much smaller parts prior to adding to the enzyme solution to get a more consistent cell solution and consistent enzyme processing profile.
The new platform is aimed at improving those pain points to reduce the surgery time, training requirements, increase the cell harvest from a given donor skin sample, and make the solution profile more consistent.
This should help with perceived value and possibly uptake. I know they were looking at this issue at least 10 years ago.

It think however the sunk cost is a big millstone and I would not think attractive to PNV in terms of margins or existing shareholder ROI expectation from a TO perspective. I think they have a way to go to get margins up and sales up consistently.